Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Clinical trial NCT06947928 · RECRUITING
Trial details
- NCT number
- NCT06947928
- Sponsor
- TuHURA Biosciences, Inc.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-11
- Primary completion
- 2027-03-31
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.